- Home
- IMCR vs FLNC Comparison
IMCR vs FLNC Comparison
Compare IMCR & FLNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- FLNC
- Stock Information
- Founded
- IMCR 2008
- FLNC 2018
- Country
- IMCR United Kingdom
- FLNC United States
- Employees
- IMCR N/A
- FLNC N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- FLNC Industrial Machinery/Components
- Sector
- IMCR Health Care
- FLNC Miscellaneous
- Exchange
- IMCR Nasdaq
- FLNC Nasdaq
- Market Cap
- IMCR 1.6B
- FLNC 802.6M
- IPO Year
- IMCR 2021
- FLNC 2021
- Fundamental
- Price
- IMCR $35.00
- FLNC $8.17
- Analyst Decision
- IMCR Buy
- FLNC Buy
- Analyst Count
- IMCR 10
- FLNC 18
- Target Price
- IMCR $58.13
- FLNC $8.58
- AVG Volume (30 Days)
- IMCR 383.2K
- FLNC 6.2M
- Earning Date
- IMCR 08-07-2025
- FLNC 08-06-2025
- Dividend Yield
- IMCR N/A
- FLNC N/A
- EPS Growth
- IMCR N/A
- FLNC N/A
- EPS
- IMCR N/A
- FLNC N/A
- Revenue
- IMCR $333,581,000.00
- FLNC $2,329,871,000.00
- Revenue This Year
- IMCR $26.82
- FLNC $3.61
- Revenue Next Year
- IMCR $8.15
- FLNC $25.79
- P/E Ratio
- IMCR N/A
- FLNC N/A
- Revenue Growth
- IMCR 25.75
- FLNC 6.08
- 52 Week Low
- IMCR $23.15
- FLNC $3.46
- 52 Week High
- IMCR $41.54
- FLNC $24.00
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- FLNC 68.98
- Support Level
- IMCR $32.20
- FLNC $6.06
- Resistance Level
- IMCR $35.75
- FLNC $8.92
- Average True Range (ATR)
- IMCR 1.31
- FLNC 0.59
- MACD
- IMCR 0.28
- FLNC 0.18
- Stochastic Oscillator
- IMCR 84.94
- FLNC 78.68
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.